Goldman Sachs’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,400
| Closed | -$2.24M | – | 6620 |
|
|
2025
Q4 | $2.24M | Hold |
6,400
| – | – | ﹤0.01% | 4484 |
|
|
2025
Q3 | $2.07M | Sell |
6,400
-900
| -12% | -$280K | ﹤0.01% | 4447 |
|
|
2025
Q2 | $2.84M | Sell |
7,300
-4,500
| -38% | -$1.81M | ﹤0.01% | 3904 |
|
|
2025
Q1 | $5.13M | Sell |
11,800
-13,400
| -53% | -$5.38M | ﹤0.01% | 3327 |
|
|
2024
Q4 | $9.3M | Buy |
25,200
+900
| +4% | +$377K | ﹤0.01% | 2868 |
|
|
2024
Q3 | $12.6M | Buy |
24,300
+1,500
| +7% | +$801K | ﹤0.01% | 2485 |
|
|
2024
Q2 | $12.4M | Sell |
22,800
-9,200
| -29% | -$4.86M | ﹤0.01% | 2300 |
|
|
2024
Q1 | $16.6M | Buy |
32,000
+12,900
| +68% | +$6.42M | ﹤0.01% | 2005 |
|
|
2023
Q4 | $9.01M | Buy |
19,100
+900
| +5% | +$416K | ﹤0.01% | 2630 |
|
|
2023
Q3 | $7.92M | Buy |
+18,200
| New | +$8.26M | ﹤0.01% | 2589 |
|
|
2023
Q1 | – | Sell |
-1,600
| Closed | -$821K | – | 6003 |
|
|
2022
Q4 | $821K | Sell |
1,600
-6,500
| -80% | -$3.3M | ﹤0.01% | 4555 |
|
|
2022
Q3 | $3.68M | Sell |
8,100
-2,600
| -24% | -$1.24M | ﹤0.01% | 3422 |
|
|
2022
Q2 | $5.16M | Buy |
10,700
+4,600
| +75% | +$2.28M | ﹤0.01% | 3101 |
|
|
2022
Q1 | $3M | Sell |
6,100
-14,300
| -70% | -$6.54M | ﹤0.01% | 3857 |
|
|
2021
Q4 | $9.46M | Buy |
20,400
+2,700
| +15% | +$1.14M | ﹤0.01% | 2824 |
|
|
2021
Q3 | $6.6M | Buy |
17,700
+4,100
| +30% | +$1.56M | ﹤0.01% | 3117 |
|
|
2021
Q2 | $5.19M | Sell |
13,600
-8,400
| -38% | -$3.21M | ﹤0.01% | 3301 |
|
|
2021
Q1 | $7.9M | Buy |
22,000
+8,000
| +57% | +$2.57M | ﹤0.01% | 2763 |
|
|
2020
Q4 | $4.5M | Sell |
14,000
-103,300
| -88% | -$31.7M | ﹤0.01% | 3083 |
|
|
2020
Q3 | $31.5M | Buy |
117,300
+103,400
| +744% | +$27.8M | 0.01% | 1372 |
|
|
2020
Q2 | $3.65M | Sell |
13,900
-6,800
| -33% | -$1.81M | ﹤0.01% | 3020 |
|
|
2020
Q1 | $4.7M | Buy |
20,700
+18,900
| +1,050% | +$5.15M | ﹤0.01% | 2698 |
|
|
2019
Q4 | $544K | Sell |
1,800
-5,900
| -77% | -$1.62M | ﹤0.01% | 4461 |
|
|
2019
Q3 | $1.85M | Buy |
+7,700
| New | +$2.11M | ﹤0.01% | 3590 |
|
|
2019
Q2 | – | Sell |
-65,500
| Closed | -$18.8M | – | 5173 |
|
|
2019
Q1 | $18.8M | Sell |
65,500
-219,800
| -77% | -$63.6M | 0.01% | 1924 |
|
|
2018
Q4 | $74.9M | Buy |
285,300
+269,200
| +1,672% | +$74M | 0.02% | 781 |
|
|
2018
Q3 | $4.41M | Buy |
16,100
+16,000
| +16,000% | +$4.15M | ﹤0.01% | 3076 |
|
|
2018
Q2 | $24K | Hold |
100
| – | – | ﹤0.01% | 5474 |
|
|
2018
Q1 | $22K | Sell |
100
-62,500
| -100% | -$14.7M | ﹤0.01% | 5657 |
|
|
2017
Q4 | $14.1M | Buy |
62,600
+23,400
| +60% | +$4.98M | ﹤0.01% | 2198 |
|
|
2017
Q3 | $7.44M | Sell |
39,200
-65,800
| -63% | -$12.5M | ﹤0.01% | 2810 |
|
|
2017
Q2 | $19.8M | Sell |
105,000
-91,500
| -47% | -$16.4M | 0.01% | 1941 |
|
|
2017
Q1 | $32.5M | Buy |
196,500
+166,400
| +553% | +$26.5M | 0.01% | 1532 |
|
|
2016
Q4 | $4.33M | Buy |
+30,100
| New | +$4.03M | ﹤0.01% | 3175 |
|
|
2016
Q1 | – | Sell |
-11,700
| Closed | -$1.63M | – | 7126 |
|
|
2015
Q4 | $1.63M | Sell |
11,700
-2,900
| -20% | -$399K | ﹤0.01% | 3819 |
|
|
2015
Q3 | $2.04M | Sell |
14,600
-8,900
| -38% | -$1.34M | ﹤0.01% | 3771 |
|
|
2015
Q2 | $3.86M | Sell |
23,500
-68,700
| -75% | -$11M | ﹤0.01% | 3185 |
|
|
2015
Q1 | $14.2M | Buy |
92,200
+49,100
| +114% | +$6.99M | ﹤0.01% | 2011 |
|
|
2014
Q4 | $5.42M | Sell |
43,100
-50,900
| -54% | -$6.29M | ﹤0.01% | 2923 |
|
|
2014
Q3 | $11.2M | Sell |
94,000
-37,700
| -29% | -$4.32M | ﹤0.01% | 2270 |
|
|
2014
Q2 | $14.2M | Sell |
131,700
-83,400
| -39% | -$8.59M | ﹤0.01% | 2085 |
|
|
2014
Q1 | $21.4M | Sell |
215,100
-198,200
| -48% | -$17.9M | 0.01% | 1710 |
|
|
2013
Q4 | $38.2M | Sell |
413,300
-849,100
| -67% | -$75.4M | 0.01% | 1247 |
|
|
2013
Q3 | $106M | Buy |
1,262,400
+742,000
| +143% | +$63.6M | 0.04% | 572 |
|
|
2013
Q2 | $42.6M | Buy |
+520,400
| New | +$38.9M | 0.02% | 1005 |
|
Other funds holding ELV
VCM
VPM
Goldman Sachs's ELV Position: Q1 2026 in Review
Goldman Sachs reduced its Elevance Health (ELV) stake by 5.4% in Q1 2026, selling an estimated $27.7M and leaving 1,476,183 shares worth $432M. The position accounts for 0.05% of the portfolio, ranked #393.
Goldman Sachs first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.06B in Q4 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Goldman Sachs held 1,476,183 shares of Elevance Health worth $432M as of Q1 2026.
- Goldman Sachs sold 84,249 Elevance Health shares in Q1 2026, an estimated $27.7M.
- Elevance Health made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #393 holding.
- Goldman Sachs first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Elevance Health position peaked at $1.06B in Q4 2022.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.